Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Sanofi says FDA approves 4-strain flu vaccine

By R&D Editors | June 10, 2013

French drugmaker Sanofi said Monday the Food and Drug Administration approved a new version of its flu vaccine Fluzone that is designed to prevent four types of the virus.

Sanofi said Fluzone Quadrivalent is designed to protect against two types of influenza A and two types of influenza B. Fluzone is the only flu shot recommended in the U.S. for infants and very young children, and Fluzone Quadrivalent is approved for children as young as six months. Sanofi also makes Fluzone HD, a high-dose vaccine intended for people over 65, whose immune systems tend not to respond as strongly.

Seasonal flu vaccines typically protect against only three strains of the flu.

The new vaccine will be available for the current flu season, Sanofi said. Flu season runs from October to May and usually peaks in late January and early February.

The U.S. Centers for Disease Control and Prevention recommends that everyone six months and older get a seasonal flu shot every year unless they have severe allergic reactions to past flu shots or to eggs, which are used in growing the vaccine, or Guillain-Barre Syndrome, a rare condition that is sometimes linked to vaccines.

Sanofi shares fell 9 cents to $53.28 in afternoon trading.

Related Articles Read More >

2022 Global Funding Forecast: Strong R&D growth with clouds on the horizon
2022 Global Funding Forecast: R&D variants cover more than the pandemic
R&D firm BourkeHood helps startups claim over $100M
2022 R&D 100 Awards now open for submissions
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars